Colorectal Surgery Obesity related morbidity during COVID-19

Abstract Tocilizumab, a monoclonal anti-IL-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe COVID-19 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report is to present a case of acute large bowel perforation in a morbidly obese patient with COVID-19 pneumonia who received empiric Tocilizumab. This case report analyzes the risks of acute large bowel perforation after using this medication empirically and discusses the appropriate management of this adverse event.